- Home
- WHLR vs ENTO Comparison
WHLR vs ENTO Comparison
Compare WHLR & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHLR
- ENTO
- Stock Information
- Founded
- WHLR 2011
- ENTO 2014
- Country
- WHLR United States
- ENTO United States
- Employees
- WHLR N/A
- ENTO N/A
- Industry
- WHLR Real Estate Investment Trusts
- ENTO Biotechnology: Pharmaceutical Preparations
- Sector
- WHLR Real Estate
- ENTO Health Care
- Exchange
- WHLR Nasdaq
- ENTO Nasdaq
- Market Cap
- WHLR 1.5M
- ENTO 1.8M
- IPO Year
- WHLR 2012
- ENTO 2016
- Fundamental
- Price
- WHLR $5.81
- ENTO $0.49
- Analyst Decision
- WHLR
- ENTO
- Analyst Count
- WHLR 0
- ENTO 0
- Target Price
- WHLR N/A
- ENTO N/A
- AVG Volume (30 Days)
- WHLR 2.9M
- ENTO 1.7M
- Earning Date
- WHLR 08-05-2025
- ENTO 05-15-2025
- Dividend Yield
- WHLR N/A
- ENTO N/A
- EPS Growth
- WHLR N/A
- ENTO N/A
- EPS
- WHLR N/A
- ENTO N/A
- Revenue
- WHLR $102,793,000.00
- ENTO N/A
- Revenue This Year
- WHLR N/A
- ENTO N/A
- Revenue Next Year
- WHLR N/A
- ENTO N/A
- P/E Ratio
- WHLR N/A
- ENTO N/A
- Revenue Growth
- WHLR 0.86
- ENTO N/A
- 52 Week Low
- WHLR $3.33
- ENTO $0.19
- 52 Week High
- WHLR $10,567.20
- ENTO $1.15
- Technical
- Relative Strength Index (RSI)
- WHLR 48.32
- ENTO 53.70
- Support Level
- WHLR $5.65
- ENTO $0.39
- Resistance Level
- WHLR $6.40
- ENTO $0.41
- Average True Range (ATR)
- WHLR 0.93
- ENTO 0.06
- MACD
- WHLR 0.21
- ENTO 0.01
- Stochastic Oscillator
- WHLR 11.09
- ENTO 61.39
About WHLR Wheeler Real Estate Investment Trust Inc.
Wheeler Real Estate Investment Trust Inc is a self-managed commercial real estate investment company. It owns, leases, and operates income-producing retail properties with a primary focus on grocery-anchored centers. The company's properties include Alex City Marketplace in Alexander City, Alabama; Bryan Station in Lexington, Kentucky; Cardinal Plaza in Henderson, North Carolina; Clover Plaza in Clover, South Carolina; Winslow Plaza in Sicklerville, New Jersey and many more.
About ENTO Entero Therapeutics Inc. Common Stock
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.